NLG-919 analog
CAY-21509-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
1402836-58-1
Formulation
A crystalline solid
Purity
≥98% (mixture of enantiomers)
MW
282,4
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
An inhibitor of IDO1 and TDO (IC50s = 79 and 25 nM, respectively, in cell-free assays); decreases kynurenine levels in cells expressing human IDO1 (EC50 = 83 nM); decreases the percentage of PD-1+ anti-CD3- and anti-CD28-activated Jurkat T cells from 0.025-1 µM; decreases tumor volume and weight and the percentage of intratumoral CD4+CD25+ Tregs in a B16/F10 murine melanoma model at 100 mg/kg when administered alone or in combination with paclitaxel
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
